Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SYRE Stock Forecast 2025-2026
$34.66
Current Price
$2.69B
Market Cap
Buy 14
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to SYRE Price Targets
+102.0%
To High Target of $70.00
+63.0%
To Median Target of $56.50
-39.4%
To Low Target of $21.00
SYRE Price Momentum
+3.4%
1 Week Change
+48.4%
1 Month Change
+31.1%
1 Year Change
+48.9%
Year-to-Date Change
-0.9%
From 52W High of $34.98
+217.7%
From 52W Low of $10.91
📊 TOP ANALYST CALLS
Did SYRE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Spyre Therapeutics is one of their latest high-conviction picks.
Latest SYRE Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, SYRE has a bullish consensus with a median price target of $56.50 (ranging from $21.00 to $70.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $34.66, the median forecast implies a 63.0% upside. This outlook is supported by 14 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Julian Harrison at BTIG, projecting a 102.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SYRE Analyst Ratings
14
Buy
0
Hold
0
Sell
SYRE Price Target Range
Low
$21.00
Average
$56.50
High
$70.00
Current: $34.66
Latest SYRE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SYRE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 1, 2025 | Jones Trading | Debanjana Chatterjee | Buy | Upgrade | $64.00 |
| Sep 26, 2025 | Deutsche Bank | David Hoang | Buy | Initiates | $43.00 |
| Sep 16, 2025 | BTIG | Julian Harrison | Buy | Reiterates | $70.00 |
| Apr 8, 2025 | Leerink Partners | Faisal Khurshid | Outperform | Initiates | $45.00 |
| Dec 11, 2024 | Jones Trading | Debanjana Chatterjee | Hold | Initiates | $N/A |
| Nov 13, 2024 | Baird | Colleen Kusy | Outperform | Maintains | $65.00 |
| Oct 25, 2024 | Guggenheim | Yatin Suneja | Buy | Maintains | $65.00 |
| Sep 4, 2024 | Wedbush | David Nierengarten | Outperform | Initiates | $45.00 |
| Jul 16, 2024 | Evercore ISI Group | Umer Raffat | Outperform | Initiates | $N/A |
| May 13, 2024 | Wells Fargo | Yanan Zhu | Overweight | Maintains | $40.00 |
| May 10, 2024 | BTIG | Julian Harrison | Buy | Maintains | $40.00 |
| May 2, 2024 | Baird | Colleen Kusy | Outperform | Initiates | $50.00 |
| Mar 26, 2024 | Stifel | Alex Thompson | Buy | Reiterates | $54.00 |
| Mar 1, 2024 | Wells Fargo | Yanan Zhu | Overweight | Upgrade | $35.00 |
| Dec 20, 2023 | BTIG | Julian Harrison | Buy | Initiates | $32.00 |
| Dec 18, 2023 | Stifel | Alex Thompson | Buy | Maintains | $27.00 |
| Dec 11, 2023 | Jefferies | Akash Tewari | Buy | Initiates | $31.00 |
| Dec 11, 2023 | Guggenheim | Buy | Initiates | $44.00 | |
| Nov 29, 2023 | TD Cowen | Tyler Van Buren | Outperform | Initiates | $N/A |
Spyre Therapeutics, Inc. (SYRE) Competitors
The following stocks are similar to Spyre Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Spyre Therapeutics, Inc. (SYRE) Financial Data
Spyre Therapeutics, Inc. has a market capitalization of $2.69B with a P/E ratio of 1.7x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -38.1%.
Valuation Metrics
Market Cap
$2.69B
Enterprise Value
$2.27B
P/E Ratio
1.7x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+18.1%
Current Ratio
10.9x
Debt/Equity
0.0x
ROE
-38.1%
ROA
-30.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Spyre Therapeutics, Inc. (SYRE) Business Model
About Spyre Therapeutics, Inc.
What They Do
Develops therapies for autoimmune and inflammatory diseases.
Business Model
Spyre Therapeutics operates as a biopharmaceutical company that generates revenue through the research and development of innovative medicines. The company focuses on bringing novel therapies to market that target the root causes of autoimmune and inflammatory conditions, thereby improving patient outcomes.
Additional Information
Spyre Therapeutics is engaged in drug discovery and development, using advanced technologies to explore new therapeutic pathways. The company has a diverse pipeline of biologic and small molecule drugs aimed at addressing specific immune system dysregulations, positioning it as a potential growth driver in the biotech sector and an attractive investment opportunity.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
65
CEO
Dr. Cameron Turtle DPHIL, Ph.D.
Country
United States
IPO Year
2016
Website
www.spyre.comSpyre Therapeutics, Inc. (SYRE) Latest News & Analysis
Latest News
Quick Summary
Spyre Therapeutics, Inc. granted stock options for 20,300 shares to two non-executive employees as part of its equity inducement plan, approved on December 1, 2025.
Why It Matters
Spyre Therapeutics is incentivizing talent with stock options, signaling confidence in growth and potential. This could enhance employee commitment and drive innovation, impacting future performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
1 month ago
Quick Summary
SPY003, a next-gen anti-IL-23 antibody, showed positive Phase 1 results, indicating good tolerance and an ~85-day half-life for potential quarterly or biannual dosing.
Why It Matters
Positive Phase 1 results for SPY003 suggest strong potential for effective long-term treatment, which could lead to increased market demand and boost the company's stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
SPY003 shows good tolerability and has an approximately 85-day half-life, indicating potential for quarterly or biannual maintenance dosing.
Why It Matters
SPY003's favorable half-life suggests potential for less frequent dosing, enhancing patient compliance and market demand, which can positively impact future revenue and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025
1 month ago
Quick Summary
Spyre Therapeutics, Inc. (NASDAQ: SYRE) announced scientific presentations at the ACR Convergence Congress, focusing on its innovative long-acting antibodies for IBD and rheumatic diseases.
Why It Matters
Spyre Therapeutics' scientific presentations could signal advancements in treatments for IBD and rheumatic diseases, potentially influencing stock performance and investor sentiment in biotech.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Spyre Therapeutics closed a public offering of 17.1 million shares at $18.50 each, raising approximately $316.2 million before expenses.
Why It Matters
Spyre Therapeutics raised $316.2 million through a public offering, strengthening its capital position for research and development in IBD treatments, potentially boosting future growth and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
1 month ago
Quick Summary
Spyre Therapeutics has launched an underwritten public offering of common stock or pre-funded warrants to certain investors to raise capital for its IBD and immune-mediated disease treatments.
Why It Matters
Spyre Therapeutics' public offering indicates potential dilution of shares, impacting stock price. Investors should assess its implications on funding growth and development in IBD treatments.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About SYRE Stock
What is Spyre Therapeutics, Inc.'s (SYRE) stock forecast for 2026?
Based on our analysis of 13 Wall Street analysts, Spyre Therapeutics, Inc. (SYRE) has a median price target of $56.50. The highest price target is $70.00 and the lowest is $21.00.
Is SYRE stock a good investment in 2026?
According to current analyst ratings, SYRE has 14 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $34.66. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SYRE stock?
Wall Street analysts predict SYRE stock could reach $56.50 in the next 12 months. This represents a 63.0% increase from the current price of $34.66. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Spyre Therapeutics, Inc.'s business model?
Spyre Therapeutics operates as a biopharmaceutical company that generates revenue through the research and development of innovative medicines. The company focuses on bringing novel therapies to market that target the root causes of autoimmune and inflammatory conditions, thereby improving patient outcomes.
What is the highest forecasted price for SYRE Spyre Therapeutics, Inc.?
The highest price target for SYRE is $70.00 from Julian Harrison at BTIG, which represents a 102.0% increase from the current price of $34.66.
What is the lowest forecasted price for SYRE Spyre Therapeutics, Inc.?
The lowest price target for SYRE is $21.00 from at , which represents a -39.4% decrease from the current price of $34.66.
What is the overall SYRE consensus from analysts for Spyre Therapeutics, Inc.?
The overall analyst consensus for SYRE is bullish. Out of 13 Wall Street analysts, 14 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $56.50.
How accurate are SYRE stock price projections?
Stock price projections, including those for Spyre Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 11, 2025 5:53 PM UTC